Cardiometabolic therapies such as mineralocorticoid receptor antagonists (MRAs), sodium glucose cotransporter 2 inhibitors (SGLT2i), and glucagon-like peptide 1 receptor agonists (GLP-1 RA) reduce clinical heart failure events in patients with heart failure with mildly reduced or preserved ejection fraction (HFpEF). This evidence concerns the gene NR3C2 and heart failure.